Full Publication Of Randomized Scandinavian Dose Escalation Trial For LS SCLC

03 Mar, 2021

Dr. Rajesh Bollam

Image

45Gy / 30 Fx / 3 weeks vs 60Gy / 40 Fx / 4 weeks

⬆️ 2a OS 74.2% vs 48.1%

⬆️ Med OS 37.2 mo vs 22.6 mo

↗️ Med PFS 18.6 mo vs 10.9 mo (p=0.13)

➡️ Grade 3+ toxicity and SAEs

First benefit of dose escalation in NSCLC / SCLC since SBRT for stage I NSCLC

Discussion

- Phase II

- Long term OS not yet available

- OS in control arm comparable to literature

- Lack of PFS & LC benefit due to difficult image interpretation ?

- FDG-PET staging & TV definition

#DrRajeshBollam #oncologistinyashoda #hematolgist #HematoOncologist #lungcancerdoctor #radiationdose #SCLC

Add a comment